Emerging data suggest Retatrutide , a dual stimulator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , could represent a promising development for weight treatment. Preliminary human tests have indicated substantial decreases in abdominal mass , conceivably exceeding other obesity therapies . Despite this, more a